Stay updated on Durvalumab and Tremelimumab in NSCLC Clinical Trial
Sign up to get notified when there's something new on the Durvalumab and Tremelimumab in NSCLC Clinical Trial page.

Latest updates to the Durvalumab and Tremelimumab in NSCLC Clinical Trial page
- Check3 days agoNo Change Detected
- Check11 days agoChange DetectedRevision history updated: added v3.5.2 and removed v3.5.0.SummaryDifference0.1%

- Check18 days agoNo Change Detected
- Check39 days agoChange DetectedRevision history shows an addition of v3.5.0 and a deletion of v3.4.3. These entries document the version updates for the page.SummaryDifference0.1%

- Check46 days agoChange DetectedRevision label updated from v3.4.2 to v3.4.3. No user-facing content or functionality changes are introduced.SummaryDifference0.1%

- Check54 days agoChange DetectedLatest history entry adds Contacts/Locations and Study Status to the study record. A deletion was recorded on 2025-09-16.SummaryDifference0.3%

- Check75 days agoChange DetectedAdded a new revision entry 'Revision: v3.4.2' to the version history. Removed the government funding lapse notice; these changes do not affect the study record content.SummaryDifference0.4%

- Check82 days agoChange DetectedAdded a site-wide notice about potential delays due to a lapse in government funding and the NIH Clinical Center’s open status, and updated the page revision to v3.4.1 (replacing v3.4.0).SummaryDifference0.4%

Stay in the know with updates to Durvalumab and Tremelimumab in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Durvalumab and Tremelimumab in NSCLC Clinical Trial page.